Prevalence and Reversibility of Lung Hyperinflation in Asthma

Completed

• Conditions: Asthma

• Registration Number: NCT01573364
• Lead Sponsor: Chiesi Farmaceutici S.p.A.

Brief Summary

The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.

Detailed Description

The other objectives are :

* the evaluation of the hyperinflation defined by an increase of the residual volume (RV),

* the observation of the relationship between the hyperinflation and the asthma characteristics,

* the study of the improvement of the functional parameters after a reversibility test

* the evaluation of the correlation between hyperinflation parameters evolution, chest tightness and dyspnea

Study Timeline

• Study Start: 2011-02
• Primary Completion: 2011-10
• Study Completion: 2012-01
• Status Verified: 2012-04
• Study First Submitted: 2012-04-05
• Study First Submitted QC: 2012-04-05
• Last Update Submitted: 2012-04-05
• Study First Posted: 2012-04-09
• Last Update Posted: 2012-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• Patient with a diagnosis of uncontrolled persistent asthma (ACT </= 19) or with an MRC score of dyspnea >/= 1
• Patient requiring a check-up including a pulmonary function test by plethysmography with a reversibility test

Exclusion Criteria

• Patient participating to an other clinical trial or having participated to a clinical trial with medicine in the last 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Laboratoire Chiesi S.A.; 🇫🇷 Courbevoie, France